首页> 美国卫生研究院文献>The Journal of Physiology >A Nav1.7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity
【2h】

A Nav1.7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity

机译:与遗传性红血丝痛相关的Nav1.7通道突变有助于神经元过度兴奋并降低利多卡因敏感性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Mutations in the TTX-sensitive voltage-gated sodium channel subtype Nav1.7 have been implicated in the painful inherited neuropathy, hereditary erythromelalgia. Hereditary erythromelalgia can be difficult to treat and, although sodium channels are targeted by local anaesthetics such as lidocaine (lignocaine), some patients do not respond to treatment with local anaesthetics. This study examined electrophysiological differences in Nav1.7 caused by a hereditary erythromelalgia mutation (N395K) that lies within the local anaesthetic binding site of the channel. The N395K mutation produced a hyperpolarized voltage dependence of activation, slower kinetics of deactivation, and impaired steady-state slow inactivation. Computer simulations indicate that the shift in activation is the major determinant of the hyperexcitability induced by erythromelalgia mutations in sensory neurons, but that changes in slow inactivation can modulate the overall impact on excitability. This study also investigated lidocaine inhibition of the Nav1.7-N395K channel. We show that the N395K mutation attenuates the inhibitory effects of lidocaine on both resting and inactivated Nav1.7. The IC50 for lidocaine was estimated at 500 μm for inactivated wild-type Nav1.7 and 2.8 mm for inactivated Nav1.7-N395K. The N395K mutation also significantly reduced use-dependent inhibition of lidocaine on Nav1.7 current. In contrast, a different hereditary erythromelalgia mutation (F216S), not located in the local anaesthetic binding site, had no effect on lidocaine inhibition of Nav1.7 current. Our observation of reduced lidocaine inhibition on Nav1.7-N395K shows that the residue N395 is critical for lidocaine binding to Nav1.7 and suggests that the response of individuals with hereditary erythromelalgia to lidocaine treatment may be determined, at least in part, by their specific genotype.
机译:TTX敏感的电压门控钠通道亚型Nav1.7的突变与疼痛的遗传性神经病,遗传性红血丝痛有关。遗传性红斑狼疮可能很难治疗,尽管钠通道是利多卡因(利多卡因)等局部麻醉剂的靶向治疗,但有些患者对局部麻醉剂的治疗没有反应。这项研究检查了由通道的局部麻醉结合位点内的遗传性红血球痛突变(N395K)引起的Nav1.7的电生理差异。 N395K突变产生激活的超极化电压依赖性,失活动力学变慢以及稳态慢失活受损。计算机模拟表明,激活的转变是由感觉神经元中的红血球痛突变引起的过度兴奋的主要决定因素,但是缓慢失活的变化可以调节对兴奋性的总体影响。这项研究还研究了利多卡因对Nav1.7-N395K通道的抑制作用。我们表明,N395K突变减弱了利多卡因对静止和失活的Nav1.7的抑制作用。灭活的野生型Nav1.7估计利多卡因的IC50为500μm,灭活的Nav1.7-N395K估计为2.8 mm。 N395K突变还显着降低了利多卡因对Nav1.7电流的使用依赖性抑制。相反,不位于局部麻醉剂结合位点的另一种遗传性红斑狼疮突变(F216S)对利多卡因对Nav1.7电流的抑制没有影响。我们对利多卡因对Nav1.7-N395K抑制作用降低的观察结果表明,残基N395对于利多卡因与Nav1.7的结合至关重要,并表明遗传性红斑狼疮患者对利多卡因治疗的反应可能至少部分取决于其特定基因型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号